Faculty Profiles - NAKATSUKA Mikiya

MISC - NAKATSUKA Mikiya

Division display 581 - 600 of about 617 ／ All the affair displays >>

Environmental chemicals exposure in utero, but not in early infancy, increases the risk of endometriosis: a new method for estimation of exposure in utero

A.Seki, N.Seki, M.Nakatsuka, T.Kudo, S.Kira

Recent Research in Gynecological Endocrinology 2001

Second trimesterに発症した長期破水症例においての肺低形成の予測

中田高公, 共同研究者, 工藤尚文, 平松祐司, 多田克彦, 中塚幹也, 熊澤一真, 井下秀司, 橋本一郎, 藤原美佐保

周産期学シンポジウム 2001

GnRH agonist, GnRH antagonistのマクロファージ、繊維芽細胞、血管内皮細胞への作用

羽原俊宏, 中塚幹也, 野口聡一, 鎌田泰彦, 小西秀樹, 高田雅代, 浅桐和男, 工藤尚文

エンドメトリオーシス研究会会誌 2001

重症妊娠中毒症妊婦血清による血管内皮細胞増殖，cell migration抑制に対するprotease阻害剤の効果

野口聡一, 中塚幹也, 小西秀樹, 羽原俊宏, 高田雅代, 浅桐和男, 工藤尚文

日本妊娠中毒症学会雑誌 2001

妊娠中毒症と血流動態?母体の上腕動脈，眼動脈，子宮動脈の検討?

中塚幹也, 高田雅代, 小西秀樹, 羽原俊宏, 浅桐和男, 野口聡一, 工藤尚文

日本妊娠中毒症学会雑誌 2001

LPS刺激による絨毛細胞の一酸化窒素（NO）産生酵素誘導、およびapoptosis発生に対するプロテアーゼインヒビターによる抑制効果

中塚幹也, 工藤尚文

Surgery Frontier 8,2,229-232 2001

青年期の産婦人科的問題

中塚幹也

第31回中国・四国大学宇保健管理研究集会報告書 ,,40-44 2001

産婦人科と性同一性障害

中塚幹也, 小西秀樹, 工藤尚文

岡山医学会雑誌 113,,273-278 2001

胸郭内子宮内膜症

中塚幹也, 川原正行, 工藤尚文

日本臨床 59,増,201-203 2001

子宮動脈血流と不育症

中塚幹也, 羽原俊宏, 工藤尚文

産婦人科治療 82,5,548-551 2001

Heme insertion, assembly, and activation of apo-neuronal nitric-oxide synthase in vitro

Andrew T. Bender, Mikiya Nakatsuka, Yoichi Osawa

Journal of Biological Chemistry 275 ( 34 ) 26018 - 26023 2000.8

Language：English Publisher：American Society for Biochemistry and Molecular Biology Inc.

It has been established that in the case of inducible NO synthase (NOS), a functionally active homodimer is assembled from the heine-deficient monomeric apo-NOS in vitro by the addition of heme, whereas the heme-deficient neuronal isoform (apo-nNOS) is at best only partially activated. In the current study we have discovered that reactive oxygen species, which can be removed by the addition of superoxide dismutase and catalase, destroy the heme and limit the activation of apo-nNOS in vitro. With the use of these improved conditions, we show for the first time that heme insertion is a rapid process that results in formation of a heme-bound monomeric nNOS that is able to form the ferrous-CO P450 complex but is unable to synthesize NO. A slow process requiring more than 90 min is required for dimerization and activation of this P450 intermediate to give an enzyme with a specific activity of approximately 1100 nmol of NO formed/min/mg of protein, similar to that of the native enzyme. Interestingly, the dimer is not SDS-resistant and is not the same dimer that forms in vivo. These studies indicate at least two intermediates in the assembly of nNOS and advance our understanding of the regulation of nNOS.

DOI： 10.1074/jbc.275.34.26018

Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts

Mikiya Nakatsuka, Kazuo Asagiri, Soichi Noguchi, Toshihiro Habara, Takafumi Kudo

Life Sciences 67 ( 10 ) 1243 - 1250 2000.7

Language：English

We investigated the effects of nafamostat mesilate, a synthetic protease inhibitor clinically used for patients with pancreatitis or disseminated intravascular coagulopathy, on NO synthesis and apoptosis in lipopolysaccharide (LPS)-treated human trophoblasts. Nafamostat mesilate or aminoguanidine, an inhibitor of NO synthase, suppressed NO synthesis and apoptosis in trophoblasts induced by LPS. Both agents also suppressed matrix metalloproteinase-2 activity induced by LPS. LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate. Protease inhibitors including nafamostat mesilate may be therapeutic agents for chorioamnionitis and various diseases including septic shock, ischemia-reperfusion injury in brain and heart, graft rejection, and acute phase inflammatory diseases, in which overproduction of NO or peroxynitrite is involved in tissue injury. (C) 2000 Elsevier Science Inc.

DOI： 10.1016/S0024-3205(00)00716-5

Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts

Mikiya Nakatsuka, Kazuo Asagiri, Soichi Noguchi, Toshihiro Habara, Takafumi Kudo

Life Sciences 67 ( 10 ) 1243 - 1250 2000.7

Language：English

We investigated the effects of nafamostat mesilate, a synthetic protease inhibitor clinically used for patients with pancreatitis or disseminated intravascular coagulopathy, on NO synthesis and apoptosis in lipopolysaccharide (LPS)-treated human trophoblasts. Nafamostat mesilate or aminoguanidine, an inhibitor of NO synthase, suppressed NO synthesis and apoptosis in trophoblasts induced by LPS. Both agents also suppressed matrix metalloproteinase-2 activity induced by LPS. LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate. Protease inhibitors including nafamostat mesilate may be therapeutic agents for chorioamnionitis and various diseases including septic shock, ischemia-reperfusion injury in brain and heart, graft rejection, and acute phase inflammatory diseases, in which overproduction of NO or peroxynitrite is involved in tissue injury. (C) 2000 Elsevier Science Inc.

DOI： 10.1016/S0024-3205(00)00716-5

Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts

Mikiya Nakatsuka, Kazuo Asagiri, Soichi Noguchi, Toshihiro Habara, Takafumi Kudo

Life Sciences 67 ( 10 ) 1243 - 1250 2000.7

Language：English

We investigated the effects of nafamostat mesilate, a synthetic protease inhibitor clinically used for patients with pancreatitis or disseminated intravascular coagulopathy, on NO synthesis and apoptosis in lipopolysaccharide (LPS)-treated human trophoblasts. Nafamostat mesilate or aminoguanidine, an inhibitor of NO synthase, suppressed NO synthesis and apoptosis in trophoblasts induced by LPS. Both agents also suppressed matrix metalloproteinase-2 activity induced by LPS. LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate. Protease inhibitors including nafamostat mesilate may be therapeutic agents for chorioamnionitis and various diseases including septic shock, ischemia-reperfusion injury in brain and heart, graft rejection, and acute phase inflammatory diseases, in which overproduction of NO or peroxynitrite is involved in tissue injury. (C) 2000 Elsevier Science Inc.

DOI： 10.1016/S0024-3205(00)00716-5

クラミジア感染に伴う卵管機能の変化:卵管通気波形の数値化による評価

羽原俊宏, 中塚幹也, 木村吉宏, 鎌田泰彦, 高田雅代, 浅桐和男, 野口聡一, 新谷恵司, 工藤尚文

日本不妊学会雑誌 2000

Heme insertion, assembly, and activation of apo-neuronal nitric oxide synthase in vitro.

Bender, A. T, Nakatsuka, M, Osawa, Y

J. Biol Chem. 2000

GnRH agonist suppressed expression of nitric oxide synthases and generation of peroxynitrite in adenomyosis

Y. Kamada, M. Nakatsuka, K. Asagiri, S. Noguchi, T. Habara, M. Takata, T. Kudo

Human Reprod 2000

子癇の薬物療法 <研究1> 周産期に痙攣発作を起こした19症例の検討—子癇，脳出血，非発作重症妊娠中毒症の比較— <研究2> 重症妊娠中毒症例の眼動脈に対するNO放出剤の影響

中塚幹也, 高田雅代, 工藤尚文

日本妊娠中毒症学会雑誌 2000

妊娠中毒症妊婦血清の血管内皮細胞への作用

野口聡一, 中塚幹也, 高田雅代, 浅桐和男, 小西秀樹, 羽原俊宏, 工藤尚文

日本妊娠中毒症学会雑誌 2000

Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts

Mikiya Nakatsuka, Kazuo Asagiri, Soichi Noguchi, Toshihiro Habara, Takafumi Kudo

Life Sciences 2000

　 PREV - NEXT 　